GlassScriptPhysician profile
Andrew Weiss
NPI 1821057449
$4,199.17
in general payments reported to CMS, 2019-2025
27 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $12.56 · 2021: $701 · 2022: $730 · 2023: $993 · 2024: $1,039 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $761.44 | 2019-2025 | Hydrus Microstent, Argos, Clareon |
| Rxsight INC | $465.52 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Regeneron Healthcare Solutions, INC. | $369.51 | 2022-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $337.05 | 2019-2022 | |
| Abbvie INC. | $308.60 | 2022-2025 | Durysta |
| Apellis Pharmaceuticals, INC. | $263.11 | 2023-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $243.44 | 2021-2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $209.67 | 2022-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $171.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $134.38 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $126.72 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $113.84 | 2024-2025 | Xdemvy |
| Biogen, INC. | $94.82 | 2022-2023 | |
| Thea Pharma INC. | $83.86 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $83.57 | 2019-2025 | Cequa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $70.33 | 2022-2023 | Vabysmo |
| Bausch & Lomb Americas INC. | $62.97 | 2022-2025 | Xiidra, Vyzulta |
| Dompe US, INC. | $51.62 | 2024-2025 | Oxervate |
| Amgen INC. | $48.47 | 2024 | Tepezza |
| Ivantis, INC | $43.99 | 2021 | |
| Eyevance Pharmaceuticals LLC | $36.12 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $33.49 | 2022-2024 | |
| Harrow Eye, LLC | $20.41 | 2023 | Iheezo |
| Rayner Intraocular Lenses Limited | $19.86 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.29 | 2021 | |
| Ocular Therapeutix, INC. | $13.38 | 2024 | Dextenza |
| Sight Sciences, INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.